An analysis of factors influencing short‐term and sustained response to infliximab treatment for Crohn's disease

Summary Background: 59–81% of patients given infliximab for Crohn's disease will respond. Although now in widespread use, little consensus exists regarding the optimal place in patient care. Recently developed guidelines have identified need for markers that predict response. Aims: We aimed to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alimentary pharmacology & therapeutics 2003-06, Vol.17 (12), p.1451-1457
Hauptverfasser:	Arnott, I. D. R., McNeill, G., Satsangi, J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antibodies, Monoclonal - therapeutic use Biological and medical sciences Chronic Disease Crohn Disease - drug therapy Female Gastrointestinal Agents - therapeutic use Humans Infliximab Infusions, Intravenous Intestinal Fistula - etiology Long-Term Care Male Medical sciences Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!